Phase III trial of Glucagon in Exercise-Induced Hypoglycemia (EIH)
Latest Information Update: 16 Mar 2021
At a glance
- Drugs Glucagon (Primary)
- Indications Exercise-induced hypoglycaemia
- Focus Adverse reactions
- 16 Mar 2021 New trial record
- 09 Mar 2021 According to Xeris Pharmaceuticals, the Company is currently finalizing expectations with the FDA for registration programs of this trial. Based on the FDA feedback for each program, the Company anticipates advancing at least one of the glucagon mini/micro dose programs.